This study showed that the non-viral piggyBac transposon system-engineered EGFR-CAR T-cell therapy is feasible and safe in the treatment of EGFR-positive advanced relapsed/refractory NSCLC patients [60]. Here, EGFR is linked to non-small cell lung carcinoma.